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Purpose: To review the English language publications addressing the effect of intravitreal beva-
cizumab (IVB) injection in a variety of eye conditions and analyze the data where possible.
Methods: Examination of data obtained using a Pubmed literature search conducted mid May 
2007 with the keywords “intravitreal bevacizumab”.
Results: A dose of 1.25 mg was used in 89.5% of 965 age-related macular degeneration (ARMD) 
cases with 47% receiving intravitreal bevacizumab as primary therapy. In 829 patients receiving 
repeated doses of 1.25 mg the mean logMAR best-corrected visual acuity (BCVA) improved 
from 0.88 at baseline to 0.74 at 4–6 weeks, 0.71 at 8–10 weeks, 0.67 at 12–14 weeks and 0.86 at 
 14 weeks. Mean central retinal thickness (CRT) decreased by 83.71 μm at 4–6 weeks, 79.52 
μm at 8–10 weeks, 92.46 μm at 12–14 weeks, and 75.64 μm at  14 weeks respectively. In 
64 patients receiving IVB for retinal vein occlusion (RVO) mean logMAR BCVA decreased 
from 1.21 at baseline to 0.83 and 0.82 at 4 and 12 weeks respectively. Mean CRT decreased 
from 635.97 μm at baseline to 320.06 μm and 346.27 μm at 4 and 12 weeks. Favorable responses 
have been reported in various other conditions.
Conclusions: Current evidence suggests that intravitreal bevacizumab, alone or as an adjunct 
to conventional therapy, has a beneﬁ  cial effect in various neovascular and edematous retinal 
conditions and is well tolerated in the short term.
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Introduction
Bevacizumab (Avastin®; Genentech, South San Francisco, CA, USA) is a monoclonal 
antibody that binds all isomers of vascular endothelial growth factor (VEGF). It was 
approved by the US Food and Drug Administration (FDA) in February 2004 for 
intravenous treatment of metastatic colorectal cancer.
Intravenous administration of bevacizumab produced signiﬁ  cant improvement in 
visual acuity and reduction of central retinal thickening in patients with age-related 
macular degeneration (ARMD) (Michels et al 2005; Moshfeghi et al 2006).
Choroidal neovascularization (CNV) due to pathological myopia was also 
suppressed by systemic bevacizumab (Nguyen et al 2005). The problem with systemic 
therapy, however, lay in the potential side-effect proﬁ  le, with thromboembolic events 
such as transient ischemic attacks, strokes, angina, and myocardial infarction having 
been reported in oncology patients (Shah et al 2005). Theoretically, decreasing 
the dose of bevacizumab would decrease the potential risk of adverse effects, and 
one method to achieve this reduction is to inject the drug directly into the vitreous 
cavity. Multiple intravitreal anti-VEGF antibody injections not only prevented iris 
neovascularization in primate eyes but also did not induce inﬂ  ammation (Adamis 
et al 1996), thus the decision was made to offer off-label intravitreal bevacizumab 
(IVB) to a patient with neovascular ARMD who continued to lose vision despite pho-
todynamic therapy (PDT) with intravitreal triamcinolone and pegaptanib injections Clinical Ophthalmology 2007:1(3) 274
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(Rosenfeld et al 2005). Within 1 week the subretinal ﬂ  uid 
in the injected eye had resolved and no inﬂ  ammation was 
observed.
Since then, off-label intravitreal bevacizumab use has 
been reported in a variety of neovascular conditions and 
this article reviews and analyzes the recent published 
results.
Methods
A literature search was conducted on Pubmed in May 2007 
using the keywords “intravitreal” and “bevacizumab”. 
English-language publications were selected that reported 
the effect of intravitreal bevacizumab in a variety of 
neovascular ocular conditions. The results pertaining to 
separate entities were grouped together and analyzed, 
where possible, after converting all reported visual acui-
ties to their logMAR equivalent. In the case of ETDRS 
letters being reported this was done by using the formula: 
logMAR = 1.7 – (0.02) (ETDRS letter score) (Cotter et al 
2003). Weighted means were calculated for the subgroups 
in order to better quantify the overall results of the different 
studies but statistical signiﬁ  cance could not be determined 
since critical data were not always available in the studies 
reviewed.
Results
Neovascular ARMD
The beneﬁ  cial effect reported by Rosenfeld et al (2005) 
prompted several investigators to study off-label IVB in 
neovascular ARMD patients.
A dose of 1.0 mg bevacizumab was used for the ﬁ  rst 
intravitreal injection but, in subsequent reports, doses used 
ranged between 1.0 mg and 2.5 mg. A dose of 1.25 mg 
was used in 864 (89.5%) of the 965 reported ARMD cases. 
Costa et al (2006) demonstrated a dose-related change in 
best-corrected visual acuity (BCVA) at week 12 in their 
study where vision improved by +0.3 ETDRS line after a 
dose of 1.0 mg, by +0.6 line after 1.5 mg, and by +1.0 line 
after 2.0 mg of IVB (p = 0.02). In 53% of 926 patients IVB 
was used after conventional treatment options did not bring 
about the desired result and 47% therefore received IVB as 
primary therapy.
Single 2.5 mg of bevacizumab injection
Table 1 shows the results of 2 studies using 2.5 mg of beva-
cizumab for intravitreal injection. In both instances the best 
corrected visual acuity (BCVA) and central retinal thickness 
(CRT) measured with ocular coherence tomography (OCT) 
showed a marked improvement at 4 weeks post-injection 
(Table 1).
Single and multiple 1.25 mg bevacizumab injections
Table 2 portrays the changes in BCVA after mostly single 
intravitreal injections of 1.25 mg bevacizumab in 35 patients. 
It is interesting to note that in the study by Moschos et al 
(2007) both CRT and BCVA showed a signiﬁ  cant improve-
ment at 4 weeks which did not last until 12 weeks, whereas 
the patients studied by Aggio et al (2006) still had signiﬁ  -
cantly improved CRT and BCVA more than 12 weeks after 
injection.
Table 3 summarizes the effect of repeated intravitreal 
injections of 1.25 mg bevacizumab on mean logMAR BCVA 
in 10 different studies. Weighted means were calculated to 
quantify the overall effect of the intervention and it was 
found that, compared with baseline, the mean BCVA had 
improved at 4–6 weeks, 8–10 weeks, and 12–14 weeks with 
the overall BCVA almost returning to the baseline value after 
14 weeks even though some of the individual studies still 
showed signiﬁ  cant improvement at this time. These ﬁ  ndings 
are depicted in Figure 1.
Table 4 shows the decrease in CRT recorded in the same 
10 studies referred to above. Weighted means were again 
calculated and showed that at all time points the mean CRT 
was still well below that at baseline as seen in Figure 2. Most 
of the individual studies providing data after 14 weeks show 
that signiﬁ  cant reductions in CRT can be maintained for 
more than 3 months with repeated IVB injections, although 
collectively the greatest reduction occurred between 12 and 
14 weeks.
When comparing Figures 1 and 2 it will be noted that 
between 12 and 14 weeks the greatest reduction in CRT coin-
cided with the greatest improvement in BCVA even though in 
Table 1 Effect of a single intravitreal injection of 2.5 mg bevaci-
zumab on median BCVA and CRT at 0 and 4 weeks in patients 
with neovascular ARMD
Authors n  =  Median   Median   Median   Median
    logMAR   logMAR   CRT in μm   CRT in μm
    BCVA   BCVA  at 0 wks  at 4 wks
    at 0 wks  at 4 wks
Bashshur   17  1.0  0.6   350  282 
et al 2006      (p = 0.001)   (p    0.001)
Abrahám- 39 1.18  0.88    388  247 
Marin et al       (p = 0.002)   (p    0.001)
2006        
Abbreviations: ARMD, age-related macular degeneration; BCVA, best corrected 
visual acuity; CRT, central retinal thickness.Clinical Ophthalmology 2007:1(3) 275
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most of the individual studies the correlation between BCVA 
and decrease in CRT was not statistically signiﬁ  cant.
Diabetic retinopathy
It is well known that VEGF plays an important role in 
diabetic retinopathy and several reports of a beneﬁ  cial effect 
on neovascularization in diabetic patients after IVB have 
been published.
In one case series (Mason et al 2006), 3 patients with 
proliferative diabetic retinopathy (PDR) received IVB and 
in all 3 cases complete regression of both neovascularization 
at the disc (NVD) and neovascularization elsewhere (NVE) 
was observed between 1 and 3 weeks post-injection. In 
3 other case studies, NVD and/or NVE regressed completely 
within 7 (Avery 2006), 8 (Friedlander and Welch 2006), 
and 30 (Isaacs and Barry 2006) days, respectively. Angi-
ographic leakage resolved completely in 73% of eyes with 
NVD and 82% of eyes with NVI after a single dose of IVB 
(Avery et al 2006) while in another study the mean area of 
actively leaking neovascularization decreased from 27.79 
± 6.29 mm² to 5.43 ± 2.18 mm² at 1 week and 5.50 ± 1.24 
mm² at 12 weeks post-injection (Jorge et al 2006). A third 
study reporting on 78 eyes of 64 patients with a minimum 
follow-up of 6 months showed a decrease in mean central 
macular thickness from 387.0 ± 182.8 μm at baseline to 
275.7 ± 108.3 μm at the end of follow-up (p   0.0001). In 
this report, 20.5% of eyes needed a second injection and 
7.7% needed a third (Arevalo et al 2007). All three studies 
demonstrated an improvement in BCVA over the treatment 
period (Table 5).
IVB has been used successfully in the treatment of 
neovascularization of the iris (NVI) in instances where both 
panretinal photocoagulation (PRP) and pars plana vitrectomy 
(PPV) have failed to halt the progression of NVI (Oshima et al 
2006). It has also been used to good effect in patients with 
recurrent vitreous hemorrhage despite complete PRP (Bakri 
et al 2006) as well as vitreous hemorrhage precluding PRP 
(Spaide and Fisher 2006). Preoperative IVB in a patient with 
a pre-retinal neovascular membrane and underlying tractional 
retinal detachment induced signiﬁ  cant regression of the neo-
vascular component and thereby facilitated removal of the 
ﬁ  brous membrane with minimal intra-operative hemorrhage 
(Chen and Park 2006).
Fifty-one patients with persistent diffuse diabetic macular 
edema despite previous treatments such as focal or panreti-
nal laser therapy, vitrectomy, and intravitreal triamcinolone 
injection were treated with IVB. Their mean logMAR VA 
improved from 0.86 ± 0.38 at baseline to 0.75 ± 0.37 and 
Table 2 Effect of mostly single intravitreal injections of 1.25 mg bevacizumab on mean logMAR BCVA and mean CRT (μm)
in neovascular ARMD
Authors n  = Baseline  Baseline  ↓CRT BCVA    ↓CRT BCVA    ↓CRT   BCVA
     CRT   BCVA  4 wks  4 wks  12 wks  12 wks   12 wks   12 wks
Moschos  18  298.5  0.62  52.72   0.57   43.5   0.60   –  –
et al 2007        (p   0.001) (p    0.05) (p  = 0.0592) (p  = 0.2261)  
Aggio   17  404.05  1.17  –  –  –  –  123.82   1.06 
et al 2006                (p = 0.032) (p  = 0.17)
Abbreviations: ARMD, age-related macular degeneration; BCVA, best corrected visual acuity; CRT, central retinal thickness.
Table 3 Effect of repeated intravitreal injection of 1.25 mg bevacizumab on mean logMAR BCVA in patients with neovascular ARMD
Authors n  =  Previous Rx (%)  Baseline   4–6 wks  8–10 wks  12–14 wks   14 wks
Avery et al 2006  81  63 (78)  1.00  0.80 (p   0.0001) 0.80  (p    0.0001) –  –
Yoganathan et al 2006  50  36 (72)  0.96  0.83 (p   0.01) 0.73  0.80  0.86  (P    0.01)
Rich et al 2006  53  40 (75)  0.94  0.82 (p   0.001) 0.76  (p  = 0.001) 0.78  (p    0.001) –
Spaide et al 2006  251  175 (69)  0.96  0.84 (p   0.001) 0.79  (p    0.001) 0.74  (p    0.001) –
Lazic et al 2007  102  0 (0)  1.07  –  –  –  0.94 (P = 0.001)
Aisenbrey et al 2006  30  4 (13)  0.78  0.59  –  0.63 (p   0.001) –
Chen et al 2007  102  56 (55)  0.60  0.50 (p   0.001) 0.40  (p    0.001) 0.40  (p    0.05) –
Giansanti et al 2007  27  14 (52)  0.72  0.74  0.80  0.68 (P = 0.40) 0.86
Emerson et al 2007  79  47 (59)  0.71  0.58 (p = 0.00037) –  0.63  (p  = 0.04) –
Goff et al 2007  54  38 (70)  0.80  –  –  –  0.7 (p = 0.03)
Weighted mean  829    0.88 (n = 829) 0.74  (n  = 673) 0.71  (n  = 564) 0.67  (n  = 592) 0.86  (n  = 233)
Abbreviations: ARMD, age-related macular degeneration; BCVA, best corrected visual acuity; CRT, central retinal thickness.Clinical Ophthalmology 2007:1(3) 276
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0.84 ± 0.41 at 6 and 12 weeks respectively while their mean 
central retinal thickness decreased from 501 ±163 μm at 
baseline to 416 ± 180 μm at 6 weeks and 377 ± 117 μm at 12 
weeks (Haritoglou et al 2006).
Neovascular glaucoma
IVB has been used to address neovascularization in neovas-
cular glaucoma (NVG) secondary to proliferative diabetic 
retinopathy (PDR), central retinal vein occlusion (CRVO) 
and central retinal artery occlusion (CRAO) (Mason et al 
2006; Vatavuk et al 2007).
A patient with NVG secondary to PDR underwent IVB 
injection since PRP was precluded by vitreous hemorrhage 
(Paula et al 2006). After 1 day the eye was pain free and both 
NVI and neovascularization of the angle (NVA) showed 
partial regression while after 1 week the NVI and NVA had 
regressed completely on iris ﬂ  uorescein angiography. At 8 
weeks the new vessels had not recurred and the IOP was 19 
mm Hg on topical timolol and brimonidine as well as oral 
acetazolamide.
Six patients with refractory NVG after retinal vein 
occlusions received IVB since the mean IOP on maximal 
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Figure 1 Effect of repeated intravitreal injections of 1.25 mg bevacizumab on mean logMAR best corrected visual acuity (BCVA). 
Table 4 Decrease (Δ) in mean CRT (μm) after repeated intravitreal injections of 1.25 mg bevacizumab in patients with neovascular 
ARMD
Authors n  =  Previous Rx (%)  Baseline CRT   4–6 wks  8–10 wks  12–14 wks   14 wks
Avery et al 2006  81  63 (78)  –  92 (p   0.0001) 89  (P    0.0001) 67  (P    0.01) –
Yoganathan et al 2006  50  36 (72)  339  70 (p   0.001)  99 63 73  (p    0.001)
Rich et al 2006  53  40 (75)  351  97.5 (p   0.001) 110.8  (P    0.001) 99.6  (P    0.001) –
Spaide et al 2006  251  175 (69)  340  93 (p   0.001) –  127  (P    0.001) –
Lazic et al 2007  102  0 (0)  378  –  –  –  56 (p = 0.01)
Aisenbrey et al 2006  30  4 (13)  –  –  –  –  –
Chen et al 2007  102  56 (55)  251  36.1 (p   0.001) 46.2  (P    0.001) 41  (P    0.05) –
Giansanti et al 2007  27  14 (52)  373  –  –  94 (P   0.01) 70  (p    0.01)
Emerson et al 2007  79  47 (59)  304  77 (p   0.00001) –  67  (P  = 0.00002) –
Goff et al 2007  54  38 (70)  362  127 (p   0.0001) –  124  (P  = 0.0004)  118 (P   0.0001)
Weighted mean  829      83.71 (n = 670) 79.52  (n  = 286) 92.46  (n  = 697) 75.64  (n  = 233)
Abbreviations: ARMD, age-related macular degeneration; CRT, central retinal thickness.Clinical Ophthalmology 2007:1(3) 277
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therapy was 36.0 ± 5.1 mmHg (Iliev et al 2006). PRP was 
performed as soon as possible thereafter and only 3 eyes 
needed further cyclodiode laser to control the IOP. At 
the end of the follow-up period the IOP was 16.8 ± 3.5 
mmHg and all the patients were symptom-free. Another 
patient with similar pathology received IVB for ocular 
discomfort despite maximal tolerated therapy and under-
going both cyclodiode laser and PRP previously (Kahook 
et al 2006). After 48 hours her discomfort had resolved 
and IOP had decreased from 48 to 22 mmHg. She was 
then able to receive further PRP and decrease her topical 
medication.
Pathologic myopia (PM)
After publication of reports about the beneﬁ  cial effect of IVB 
in neovascular ARMD, various centers offered this treat-
ment to patients with CNV secondary to pathologic myopia 
(mCNV). Many of these patients had already undergone one 
or more treatments with PDT without much success.
In one study, 8 eyes of 8 patients with mCNV were treated 
with IVB (Sakaguchi et al 2006). Angiographic leakage 
from the CNV was reduced in 87.5% of eyes with mean 
decimal Snellen BCVA improving from 0.26 to 0.51, mean 
CNV size decreasing from 0.72 ± 0.78 disc areas (DA) to 
0.64 ± 0.73 DA, and mean foveal thickness decreasing from 
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Figure 2 Decrease (Δ) in central retinal thickness (CRT) (μm) after repeated 1.25 mg bevacizumab injections in patients with neovascular age-related macular 
degeneration.
Table 5 Effect of intravitreal bevacizumab on BCVA in patients with diabetic retinopathy
Authors n  =  Dose  Mean follow-up  Mean logMAR  Mean logMAR
        BCVA at 0 wks  BCVA at end of study
Avery et al 2006  45  6.2 μg–1.25 mg  5 wks  1.00  0.796
Jorge et al 2006   15  1.5 mg  12 wks  0.90  0.77
Arevalo et al 2005  78  1.25 mg or 2.5 mg  6.31 ± 0.81 months  0.87  0.6
Weighted mean  138      0.92  0.68
Abbreviations: BCVA, best corrected visual acuity.Clinical Ophthalmology 2007:1(3) 278
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198.4 ± 66.5 μm to 155.1 ± 74.6 μm. Eleven eyes of 9 patients 
received IVB in another small study (Yamamoto et al 2006) 
where 5 of the eyes had previously been treated with PDT. 
Mean VA improved by +3.5 lines and mean central foveal 
thickness improved from 340 μm to 234 μm.
One patient (Tewari et al 2006), whose VA remained 
20/200 6 weeks after PDT, received 2 doses of IVB 6 months 
apart and on ﬁ  nal examination had a VA of 20/25 and no 
sub-retinal ﬂ  uid on OCT examination. Similar results are also 
reported in another case series (Laud et al 2006).
Retinal vein occlusion
Macular edema resulting from central retinal vein occlusion 
(CRVO) often responds favorably to intravitreal injection of 
triamcinolone acetonide (Greenberg et al 2002; Park et al 2003). 
IVB has been used in instances where triamcinolone acetonide 
did not have the desired effect on macular edema or caused 
either progression of cataract or raised intraocular pressure.
Three separate studies examined the effect of 1.25 mg 
IVB injections on BCVA and CRT in patients with macular 
edema secondary to different types of retinal vein occlusion. 
The results are summarized in Tables 6 and 7.
After calculating weighted means, the BCVA showed 
marked improvement at 4 weeks and remained stable at 12 weeks 
whereas CRT decreased signiﬁ  cantly after 4 weeks but then 
showed a small increase by 12 weeks. These ﬁ  ndings are depicted 
in Figures 3 and 4. Similar favorable results were noted in other 
single case reports (Rosenfeld et al 2005; Spandau et al 2006).
Seven patients with macular edema secondary to ischemic 
central or hemicentral retinal vein occlusion (RVO) received 
intravitreal injections of 2.0 mg bevacizumab at 12-week 
intervals (Costa et al 2007). Mean logMAR BCVA improved 
from 1.21 at baseline to 0.68 at 25-week follow-up while CRT 
and total macular volume respectively improved from 730.1 
μm and 17.1 mm³ at baseline to 260.3 μm and 9.0 mm³ at 
25 weeks.
One patient with a BRVO and 2 patients with CRVO 
were treated with IVB but, after an initial favorable response, 
developed rebound macular edema in excess of what was noted 
before the ﬁ  rst intravitreal injection (Matsumoto et al 2007).
In an interesting case where a patient developed bilateral 
combined central retinal artery occlusion and central retinal vein 
occlusion as a result of thrombotic thrombocytopenic purpura 
secondary to adult-onset Still’s disease, IVB combined with PRP 
brought about resolution of iris neovascularization and thus pre-
cluded the need for cyclo-photoablation (Schwartz et al 2006).
Other reported uses of intravitreal 
bevacizumab
The use of IVB has been attempted with varying degrees 
of success in a variety of retinal conditions other than those 
already discussed (Table 8).
A patient with subfoveal CNV related to angioid streaks 
and VA of counting ﬁ  ngers at 2 metres was treated with 
2 injections of IVB 7 weeks apart. Eighteen weeks later the 
VA in the affected eye was 20/30 (Teixeira et al 2006). IVB 
was also used in a patient with serous detachment of the mac-
ula and extensive sub-retinal hemorrhage from peripapillary 
CNV. Within 3 months the serous detachment had completely 
resolved and the patient’s BCVA had improved from 0.16 
Table 6 Effect of intravitreal injection of bevacizumab on BCVA in RVO patients receiving a dose of 1.25 mg
Authors Type  of  RVO  N  = Baseline  4  wks  12  wks
Iturralde et al 2006  CRVO  16   1.48  1.05 (p = 0.001)  0.84 (p   0.001)
Pai et al 2007  9 CRVO and 12 BRVO  21  1.28  0.83 (p = 0.001) 0.95  (p  = 0.001)
Rabena et al 2007   BRVO  27  1.0  0.69  0.70
Weighted mean    64  1.21  0.83  0.82
Abbreviations: BCVA, best corrected visual acuity; RVO, retinal vein occlusion.
Table 7 Effect of intravitreal injection of bevacizumab on CRT (μm) in RVO patients receiving a dose of 1.25 mg
Authors Type  of  RVO  N  = Baseline  4  wks  12  wks
Iturralde et al 2006   CRVO  16   887  372 (p   0.001) –
Pai et al   9 CRVO and 12 BRVO  21  647.81  293.43 (p = 0.001) 320.90  (p  = 0.001)
Rabena et al 2007   BRVO  27  478  310  366
Weighted mean      635.97 (n = 64) 320.06  (n  = 64) 346.27  (n  = 48)
Abbreviations: CRT, central retinal thickness; RVO, retinal vein occlusion.Clinical Ophthalmology 2007:1(3) 279
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decimal Snellen to 1.0 (Soliman et al 2006). Similarly, VA 
improved from 20/40−1 to 20/20 over a 24-week period in a 
patient with idiopathic juxtafoveal retinal telangiectasis and 
juxtafoveal subretinal neovascularization (Jorge et al 2006).
Another patient with retinal neovascularization and vitre-
ous hemorrhage secondary to sickle cell retinopathy received 
IVB after declining vitrectomy with endophotocoagulation. 
Four weeks later, the VA had improved from 20/60 to 20/20, 
the neovascularization had regressed and scatter laser pho-
tocoagulation could be applied (Siqueira et al 2006). Two 
patients with pseudophakic cystoid macular edema refrac-
tory to conventional medical treatment received IVB which 
resulted in a marked VA improvement in both cases (Mason 
et al 2006). IVB also caused regression of iris, retinal, and 
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Figure 3 Effect of 1.25 mg intravitreal bevacizumab injection on mean logMAR best corrected visual acuity (BCVA) in retinal vein occlusion patients (n = 64).
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choroidal neovascularization in a case of anterior segment 
ischemia caused by laser ablation for aggressive posterior 
retinopathy of prematurity (Shah et al 2007). IVB was 
attempted in 6 patients with chronic macular edema due to 
uveitis but, although well tolerated, none of the patients had 
signiﬁ  cant improvement in either visual acuity or central 
retinal thickness after 1 month (Ziemssen et al 2007).
Nine patients with idiopathic CNV, 2 with CNV second-
ary to central serous chorioretinopathy (CSCR), and 4 with 
CNV attributed to punctuate inner choroidopathy (PIC) 
received monthly 1.25 mg IVB injections for 3 months (Chan 
et al 2007). Mean logMAR BCVA improved from 0.48 at 
baseline to 0.25 at 1 month and 0.17 at 6 months (both p = 
0.001) while mean CRT declined from 306 μm at baseline 
to 201 μm at 6 months (p   0.001). No recurrences were 
observed at 6 months. Both BCVA and CRT also improved 
signiﬁ  cantly after IVB in 10 eyes with idiopathic CNV refrac-
tory to posterior subtenon triamcinolone injection for more 
than 3 months (Gomi et al 2007).
Twenty-three patients with retinal angiomatous pro-
liferation (RAP) were treated with 1.25 mg IVB during a 
3-month period (Meyerle et al 2007). Median logMAR visual 
acuity improved from 0.60 at baseline to 0.48 at both 1 and 
3 months. Mean CRT improved from 335 μm at baseline to 
202 μm at 1 month and 209 μm at 3 months. Nine eyes had 
pigment epithelial detachments (PEDs) at baseline and only 
2 PEDs were present at 1 month. Similar results were reported 
in 16 other patients with RAP (Joeres et al 2007).
Discussion
Several chemical mediators have been implicated in the 
regulation of intraocular neovascularization. These include 
angiopoietin (Otani et al 1999), pigment epithelium-derived 
factor (PEDF) (Holekamp et al 2002), ﬁ  broblast growth fac-
tor (Schlingemann 2004), and VEGF.
VEGF promotes the proliferation and migration of 
vascular endothelial cells and organizes these cells into 
functioning tubules. It increases vascular permeability and 
is involved in vessel maturation and regression as well as 
ocular inﬂ  ammation (Ferrara 2004; Adamis and Shima 
2005). As such, it is believed to be a key factor in the 
development and progression of both CNV (Ishibashi et 
al 1997) and ischemia-induced retinal neovascularization 
(Ishida et al 2003).
Intravitreal injection of VEGF into normal primate eyes 
causes microvascular occlusion with ischemia, telangiecta-
sis, and even micro-aneurysm formation – all features of 
diabetic retinopathy (Tolentino et al 1996, 2002). Not only 
do VEGF levels show a correlation with the severity of pro-
liferative diabetic retinopathy but also a reduction in levels 
once the retinopathy has been successfully treated with laser 
photocoagulation (Aiello et al 1994). VEGF injection can 
induce iris neovascularization and neovascular glaucoma 
(Tolentino et al 1996) and it plays an important role in 
the pathogenesis of diabetic macular edema by increasing 
vascular permeability (Funatsu et al 2006).
Over the past few decades various modalities have 
become available for the treatment of neovascular ocular 
diseases but all of these have had limitations. Photodynamic 
therapy (PDT) with verteporﬁ  n (Novartis Ophthalmics, 
Duluth, GA, USA), alone or in combination with intravitreal 
injection of triamcinolone acetonide, reduces the risk of 
vision loss in patients suffering from exudative ARMD but, 
despite this reduction in risk, the mean visual acuity decreases 
over time (TAP 1999; VIP 2001). PDT is also approved for 
treatment of subfoveal CNV in pathologic myopia (PM) but 
in one study, despite showing beneﬁ  t at 1 year, no statistically 
signiﬁ  cant treatment beneﬁ  t was demonstrated at 2 years 
(VIP 2003).
Laser thermal photocoagulation is used in a variety of 
retinal neovascular diseases (MPSG 1991) but, due to pho-
toreceptor damage, is no longer indicated for the treatment 
of subfoveal CNV in conditions such as ARMD and PM. 
Indocyanine green-mediated photothrombosis (Arevalo et al 
2005) and transpupillary thermotherapy (Connoly et al 2005) 
have also been described in the treatment of CNV.
The idea of inhibiting or counteracting angiogenic factors 
is not new. In 1948, Michaelson proposed the role of growth 
factors in the development of vascular diseases of the retina 
(Michaelson 1948) and in 1971 Folkman suggested that 
Table 8 Other reported uses of intravitreal bevacizumab
•  CNV related to angioid streaks
• Peripapillary  CNV
•  Idiopathic juxtafoveal retinal telangiectasis (Moon et al 2007)
•  Sickle cell retinopathy
•  Pseudophakic cystoid macular edema
•  Anterior segment ischemia
•  Chronic uveitic macular edema (no signiﬁ  cant improvement)
• Idiopathic  CNV
•  CNV secondary to central serous chorioretinopathy
•  CNV secondary to punctate inner choriodopathy
•  Retinal angiomatous proliferation
•  Radiation maculopathy (Ziemssen et al 2007)
•  Cystoid macular edema in retinitis pigmentosa (Melo et al 2007)
•  Radiation optic neuropathy (Finger 2007)
•  Eales disease (Kumar and Sinha 2007)
• Adjunct  to  ﬁ  ltering surgery (Jonas et al 2007)
Abbreviation: CNV, choroidal neovascularization.Clinical Ophthalmology 2007:1(3) 281
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inhibiting these factors may have therapeutic implications 
in the treatment of cancer (Folkman 1971).
Pegaptanib sodium (Macugen®; Eyetech Pharmaceuti-
cals, New York, NY) is an aptamer that binds VEGF isomer 
165 (Gragoudas et al 2004) and was the ﬁ  rst anti-VEGF 
drug to be approved by the FDA in December 2004 for 
intravitreal injection in the treatment of CNV. Patients 
treated with repeated intravitreal injections of pegaptanib 
experienced a slower rate of vision loss when compared 
with a control group after 1 year although only 6% had a 
signiﬁ  cant improvement in vision as compared with 2% in 
the control group.
Ranibizumab (Lucentis®; Genentech, South San 
Francisco, CA) is an antigen binding fragment (Fab) devel-
oped from a full-length recombinant humanized monoclonal 
antibody with the purpose of improving retinal penetration 
due to its smaller size. Unlike pegaptanib it binds to all 
isoforms of VEGF. In a recent study, patients were treated 
with 24 monthly intravitreal injections of 0.3 or 0.5 mg 
ranibizumab. At 12 months, 94.5% (0.3 mg) and 94.6% 
(0.5 mg), respectively, lost fewer than 15 letters as opposed 
to 62.2% in the control group. Of note, visual acuity improved 
by  15 letters in 24.8% (0.3 mg) and 33.8% (0.5 mg) 
compared with 5.0% in the control group (Rosenfeld et al 
2006). Ranibizumab received FDA approval for intravitreal 
use on 30 June 2006.
Bevacizumab (Avastin®; Genentech, South San Fran-
cisco, CA) is the full-length monoclonal antibody that was 
initially considered to be too large to penetrate the retina and 
thus led to the development of its derivative ranibizumab. 
It also binds all isomers of VEGF (Ferrara et al 2004) but, 
unlike ranibizumab with a single VEGF binding site, it has 
two VEGF binding sites that increase its overall dissociation 
constant for VEGF to between 0.5 and 1.0 nM compared with 
0.140 nM for ranibizumab (Chen et al 1999).
In the literature under review, intravitreal injection of 
bevacizumab showed a deﬁ  nite improvement in both BCVA 
and central retinal thickness in a variety of neovascular 
conditions affecting the eye. In neovascular ARMD it not 
only improved these parameters in the 53% of patients who 
had already received more conventional forms of treatment 
but also in the 47% who received IVB as primary therapy. 
One study even suggested that patients receiving IVB as 
primary treatment fared better than those who had previ-
ously undergone other treatment. The literature shows that 
the beneﬁ  cial effect of a single IVB injection lasts up to 
12 weeks but also that this effect is prolonged by repeated 
injections of the drug.
IVB appears useful in addition to different forms of 
laser therapy in both diabetic retinopathy and neovascular 
glaucoma. It not only causes regression of new vessels 
when conventional photocoagulation appears to have been 
unsuccessful but can also keep neovascularization in check 
in patients with vitreous hemorrhage until such time as the 
view of the fundus has improved and laser photocoagulation 
can be applied. IVB may facilitate the use of focal laser in 
exudative diabetic maculopathy by decreasing macular swell-
ing and thereby improving uptake of the laser burns. The 
report (Chen and Park 2006) that preoperative IVB reduces 
the neovascular component of ﬁ  brovascular membranes in 
advanced diabetic retinopathy and therefore makes the surgi-
cal removal technically easier will probably be of interest to 
retinal surgeons worldwide. The rapid resolution of pain and 
possible preclusion of diode laser cycloablation and systemic 
acetazolamide from the treatment of neovascular glaucoma 
are exciting prospects in a condition that can prove difﬁ  cult 
to manage.
In pathologic myopia, it is interesting to note that IVB 
had a beneﬁ  cial effect on BCVA, mean CNV size and central 
retinal thickness even in cases where multiple treatments 
with PDT were not successful (Sakaguchi et al 2006). This 
brings hope in a condition that until now has caused severe 
visual loss with a poor prognosis in young and middle-aged 
patients. IVB, like intravitreal triamcinolone, improves 
BCVA and macular swelling in patients with RVO. The 
obvious advantage of IVB is that, unlike triamcinolone, it 
has thus far not been shown to increase intraocular pressure 
or expedite cataract formation.
Apart from its apparent efﬁ  cacy, IVB also appears to 
be relatively safe in the short-term with no cases of ocular 
toxicity, retinal detachment, raised intraocular pressure, or 
thrombo-embolic events being reported in any of the litera-
ture reviewed. However, 2 cases of acute endophthalmitis 
occurred 2 days after IVB and coagulase-negative staphy-
lococci were isolated from vitreous specimens in both cases 
(Aggio et al 2007) while two potentially drug-related adverse 
events (ischemic stroke and myocardial infarction) where 
reported elsewhere. One study reported a 20.5% incidence 
of mild anterior chamber inﬂ  ammation not requiring any 
treatment while another reported 2 out of 224 patients (0.8%) 
with mild vitritis 1 month after injection. Another study 
reporting side effects other than commonly encountered 
subconjunctival hemorrhage and local conjunctival hyper-
emia after injection noted 2 retinal pigment epithelium rips 
and 10 posterior vitreous detachments in 102 patients, while 
several other authors have also encountered retinal pigment Clinical Ophthalmology 2007:1(3) 282
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epithelium tears after injecting IVB for neovascular AMD 
(Meyer et al 2006; Nicolo et al 2006; Shah et al 2006). A 
case of mild anterior uveitis that responded well to topical 
steroids has also been reported (Pieramici et al 2006).
As alluded to earlier, there are several limitations in 
compiling a review such as this one. Inconsistency in both 
the methods of acquisition and reporting of data, lack of 
standardized treatment protocols, variable timing of fol-
low-up visits, the retrospective nature of most reports, lack 
of controls, and relatively high percentage of patients lost 
to follow-up all play a role in this regard. However, despite 
these limitations it is still possible to gain a better overall 
impression of the effect of IVB in several different ocular 
diseases and begin to quantify its effect.
Conclusion
It appears as if IVB, despite its off-label use, is both efﬁ  ca-
cious and relatively safe in the short-term when used for 
a variety of neovascular ocular conditions and at present 
is a useful adjunct to conventional treatment. Potential 
advantages include the fact that it is much cheaper than the 
other VEGF inhibitors already approved for intravitreal use 
and, in animal studies, has a longer half-life in the vitreous 
than, for example, ranibizumab. Potential disadvantages 
include the still relatively short half-life which necessitates 
frequent re-injection to maintain the beneﬁ  cial effect and 
subsequent exposure to the risks that accompany any intra-
vitreal injection.
The results reviewed in this article need to be conﬁ  rmed 
by large prospective, randomized trials using carefully stand-
ardised protocols with regard to inclusion/exclusion criteria, 
dosages injected, criteria for and timing of re-injection, fol-
low-up intervals, and duration of treatment in an attempt to 
better clarify the exact indications for IVB as well as duration 
of beneﬁ  cial effect and optimal dose of IVB. There can, how-
ever, be little doubt that once longer-acting VEGF-inhibitors 
become available that can possibly be administered by less 
invasive routes the need for destructive laser procedures and 
even posterior vitrectomy will diminish.
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